Arch Intern Med. 2009;169(16):1491–9.PubMedCrossRef 6. Fihn SD, Gardin JM, Abrams J, et al. American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354–471.PubMedCrossRef 7. Atmakuri SR, Gollob MH, Kleiman Selleckchem 10058-F4 NS. Stable Angina. SIS3 solubility dmso In: Rosendorff C, editor. Essential cardiology: principles and practice. 2nd ed. Totowa: Humana Press; 2005. p. 451–70. 8. Ranexa [package insert]. Foster City, CA; Gilead Sciences, Inc.; 2011. 9. Chaitman BR, Pepine CJ, Parker JO, for the Combination
Assessment of Ranolazine In Stable Angina (CARISA) Investigators, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–16.PubMedCrossRef 10. Mehta PK, Goykhman P, Thomson LEJ, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive selleck coronary artery disease. JACC Cardiovasc Imaging. 2011;4(5):514–22.PubMedCrossRef Tacrolimus (FK506) 11. Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on disease-specific
health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes. 2008;1(2):107–15.PubMedCrossRef 12. Guy W. ECDEU Assessment Manual For Psychopharmacology, DHEW Publication No. ADM 76–338. Washington, DC: US Government Printing Office; 1976. 13. Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. Circulation. 2002;106(1):43–9.PubMedCrossRef 14. Venkitachalam L, Kip KE, Mulukutla SR, et al. for the NHLBI-sponsored Dynamic Registry Investigators. Temporal trends in patient-reported angina at one year after percutaneous coronary revascularization in the stent era: a report from the NHLBI-sponsored 1997–2006 dynamic registry. Circ Cardiovasc Qual Outcomes. 2009;2(6):607–15. 15. Weintraub WS, Spertus JA, Kolm P, for the COURAGE Trial Research Group, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677–87.PubMedCrossRef 16. Boden WE, O’Rourke RA, Teo KK, for the COURAGE Trial Research Group, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.PubMedCrossRef 17. Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA, for the RITA-2 Trial Participants.